Moleculin Biotech, Inc.
General ticker "MBRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $297.6M (TTM average)
Moleculin Biotech, Inc. does not follow the US Stock Market performance with the rate: -37.7%.
Estimated limits based on current volatility of 3.5%: low 2.39$, high 2.56$
Factors to consider:
- Total employees count: 19 as of 2022
- Top business risk factors: Regulatory and compliance, Insufficient funding, Economic downturns and volatility, Market competition, Labor/talent shortage/retention
- Current price 69.0% below estimated low
- Earnings for 12 months up through Q4 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [16.24$, 60.22$]
- 2025-12-31 to 2026-12-31 estimated range: [7.79$, 29.91$]
Financial Metrics affecting the MBRX estimates:
- Negative: with PPE of -0.4 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -392.00 <= 0.07
- Negative: negative Net income
- Negative: negative Industry operating income (median)
- Negative: 19.49 < Shareholder equity ratio, % of 35.33 <= 42.60
- Negative: negative Industry operating cash flow (median)
Short-term MBRX quotes
Long-term MBRX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $30.64MM | $29.63MM | $26.64MM |
| Operating Income | $-30.64MM | $-29.63MM | $-26.64MM |
| Non-Operating Income | $1.61MM | $0.37MM | $5.87MM |
| R&D Expense | $18.97MM | $19.49MM | $17.73MM |
| Income(Loss) | $-29.02MM | $-29.26MM | $-20.77MM |
| Profit(Loss)* | $-29.02MM | $-29.26MM | $-20.77MM |
| Stockholders Equity | $52.19MM | $26.07MM | $5.98MM |
| Assets | $57.42MM | $38.22MM | $16.93MM |
| Operating Cash Flow | $-27.64MM | $-23.59MM | $-23.86MM |
| Capital expenditure | $0.07MM | $0.12MM | $0.01MM |
| Investing Cash Flow | $-0.07MM | $-0.12MM | $-0.01MM |
| Financing Cash Flow | $-0.02MM | $4.14MM | $4.63MM |
| Earnings Per Share** | $-380.52 | $-370.25 | $-150.81 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.